In type 2 diabetes, weekly semaglutide reduced HbA1c and increased weight loss more than weekly exenatide ER | ACP Diabetes Monthly
Exenatide is still an effective alternative for patients who cannot tolerate semaglutide due to gastrointestinal adverse events, noted the ACP Journal Club commentary.
Intensive weight management in primary care improved weight loss and remission of type 2 diabetes | ACP Diabetes Monthly
The author of an ACP Journal Club commentary said that the intervention effect was strong enough to prompt a reconsideration of primary care management of obesity and that the results of the trial may motivate patients to lose enough weight to
Review: Adding a DPP-4 inhibitor to an SGLT-2 inhibitor reduces genital, but not genitourinary, tract infections | ACP Diabetes Monthly
The authors of an accompanying ACP Journal Club commentary noted that although the risk for bias in the five reviewed studies was reportedly low, the results were imprecise and inconsistent, leaving little confidence in the evidence of an apparent
The results are in accordance with guidelines and regulatory policy recommendations that have extended use of metformin to individuals with mild to moderate kidney impairment, an ACP Journal Club commentary said.
Review: Evidence is inconclusive on metabolic surgery vs. medical treatment for microvascular complications in T2DM | ACP Diabetes Monthly
A meta-analysis from earlier this year that compared the effects of metabolic surgery and medical treatment found 10 studies to include, only three of them randomized controlled trials.
ACP Diabetes Monthly delivers a monthly summary of news about diabetes, including the latest research, clinical guidelines, and FDA drug actions.
In high-risk T1DM, real-time continuous glucose monitoring vs self-monitoring reduced hypoglycemic events | ACP Diabetes Monthly
The study provides compelling evidence for clinicians to recommend real-time continuous glucose monitoring to their patients at high risk for severe hypoglycemia, the ACP Journal Club commentary said.
In type 2 diabetes with CVD and kidney disease, empagliflozin reduced mortality and hospitalization | ACP Diabetes Monthly
If the results are confirmed, sodium–glucose co-transporter-2 inhibitors will become a dominant strategy over standard glucose-lowering therapies for treating diabetic kidney disease, according to the ACP Journal Club commentary.
Two reviews analyze efficacy of newer drug classes in type 1 and type 2 diabetes | ACP Diabetes Monthly
The evidence favors glucagon-like peptide 1 agonists and, particularly, sodium–glucose cotransporter 2 inhibitors for type 2 diabetes, but the benefits in type 1 diabetes remain speculative, said an ACP Journal Club commentary.
Review compares effectiveness, cost, and safety of second-line drugs for diabetes | ACP Diabetes Monthly
The review found that sulfonylureas were more cost-effective than newer agents, but an ACP Journal Club commentary stressed the importance of shared decision making in the choice of a second agent.